← Peptide Index/Retatrutide

Disclaimer: This site is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before using any peptide or supplement.

Retatrutide

Metabolic

Also known as: GLP-3 R (Retatrutide analog), GLP-3 R, LY3437943

🧪 Reconstitution Guide for Retatrutide

Dose calculator, BAC water volumes, and syringe unit tables.

See Reconstitution Guide →

💰 Vendor Pricing Comparison

See all vendors that carry Retatrutide, sorted by price.

See Pricing Comparison →

Overview

Retatrutide is a novel triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly. In Phase 2 clinical trials it demonstrated the highest percentage weight loss of any single therapeutic agent studied to date, with Phase 3 trials ongoing as of 2024–2025.

Mechanism of Action

Retatrutide activates three receptors simultaneously: GLP-1 receptors to reduce appetite and improve glycemic control; GIP receptors to augment insulin secretion and lipid metabolism; and glucagon receptors to increase energy expenditure and hepatic fat oxidation. This triple agonism produces synergistic and profound metabolic effects.